Together, these findings provide support for screening checkpoint proteins, such as PD1, PD-L1, IDO, and CTLA-4 in post-surgical uterine sarcomas as they provide the means for the utilization of targeted immunotherapies in these rare but aggressive uterine sarcomas. This evidence concerns the gene CTLA4 and uterine corpus sarcoma.